All In Biotech

Drug Trial Radar · NCT05652894

A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer

A Randomized Phase III Study of HX008 (a Humanized Monoclonal Antibody Against PD-1) Compared to Investigator's Choice Chemotherapy in the First-Line Treatment of Subjects With Microsatellite Instability-High (MSI-H)/Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: May 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 190 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

190

Planned (sponsor's estimate)

Start

Feb 28, 2023

Primary completion

Jun 30, 2026

Study completion Oct 20, 2028

Sponsor

Sponsor type
Industry
First posted
Dec 15, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS), achieved by HX008 or Investigator's Choice Chemotherapy in participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic colorectal cancer (mCRC).

Conditions

  • Metastatic Colorectal Cancer

Interventions

  • HX008(Pucotenlimab)Drug

    Drug: HX008(Pucotenlimab) 200 mg ,Q3W

  • Investigator's Choice ChemotherapyDrug

    Drug: bevacizumab 5mg/kg given by IV every 14 days. Other Name: Avastin Drug: cetuximab 400 mg/m2 for the first dose, then 250 mg/sqm, intravenous infusion, repeated weekly; or Cetuximab 500 mg/ sqm, intravenous infusion, D1, repeated every 2 weeks. Other Name: Erbitux Drug: oxaliplatin 85 mg/sqm by IV, day1. Component of mFOLFOX6. Drug: irinotecan 180 mg/sqm by IV, day1.Component of FOLFORI. Drug: calcium Folinate 400 mg/sqm by IV, day1.Component of mFOLFOX6 or FOLFORI. Drug: 5-fluorouracil 400 mg/sqm, day1,followed by 2400 mg/sqm iv infusion over 46\~48 h.Component of mFOLFOX6 or FOLFORI. Drug: oxaliplatin 130 mg/sqm, intravenous infusion over 2 h ± 30 min, Day 1. Component of CAPEOX. Drug: capecitabine 1000 mg/sqm administered orally twice daily, Days 1-14. Component of CAPEOX. Drug: bevacizumab 7.5 mg/kg, intravenous infusion, D1, repeated every 3 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Independent Review Committee(IRC)Time frame: 2 years

Locations

63 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medical University

    Bengbu, Anhui, China

  • The Fifth Affiliated Hospital of Anhui Medical University

    Fuyang, Anhui, China

  • Anhui Provincial Cancer Hospital

    Hefei, Anhui, China

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

  • Peking University Cancer Hospital

    Beijing, Beijing Municipality, China

  • Peking University First Hospital

    Beijing, Beijing Municipality, China

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China

  • Gansu Provincial People's Hospital

    Lanzhou, Gansu, China

  • The Eighth Affiliated Hospital of Southern Medical University

    Foshan, Guangdong, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

  • The Sixth Affiliated Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China

  • Meizhou People's Hospital(Huangtang Hospital)

    Meizhou, Guangdong, China

  • The First Affiliated Hospital of Shantou University Medical College

    Shantou, Guangdong, China

  • Guangxi Medical University Affiliated Tumor Hospital

    Nanning, Guangxi, China

  • Guizhou Provincial People's Hospital

    Guiyang, Guizhou, China

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, China

  • The Second People's Hospital of nayang City

    Nanchangcun, Henan, China

  • Nanyang Central Hospital

    Nanyang, Henan, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Hubei Cancer Hospital

    Wuhan, Hubei, China

  • Wuhan Central Hospital

    Wuhan, Hubei, China

  • Changde First People's Hospital

    Changde, Hunan, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • Huai'an First People's Hospital

    Huaian, Jiangsu, China

  • Jiangsu Cancer Hospital

    Nanjing, Jiangsu, China

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China

  • Affiliated Qidong Hospital of Nantong University

    Nantong, Jiangsu, China

  • Suzhou Ninth People's Hospotal

    Suzhou, Jiangsu, China

  • Xuzhou Central Hospital

    Xuzhou, Jiangsu, China

  • First Affiliated Hospital of Gannan Medical University

    Ganzhou, Jiangxi, China

  • Ganzhou Municipal Hospital

    Ganzhou, Jiangxi, China

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • China-Japan Union Hospital of Jilin University

    Changchun, Jilin, China

  • Liaoning Health Industry Group Fukuang General Hospital

    Fushun, Liaoning, China

  • General Hospital of the Northern Theater Command of the Chinese People's Liberation Army

    Shenyang, Liaoning, China

  • The First Hospital of China Medical University

    Shenyang, Liaoning, China

Showing 40 of 63 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.